ALLURION TECHNOLOGIES, INC. (ALUR)
ALLURION TECHNOLOGIES, INC. (ticker ALUR) is a medical technology company developing and commercializing swallowable gastric balloon systems designed to treat obesity and support weight loss without surgery. The company operates in the medical devices and weight management sectors, offering a non-surgical alternative to traditional bariatric procedures.
What the company does
Allurion Technologies develops proprietary gastric balloon systems for weight loss. The company’s flagship product is the Allurion Gastric Balloon, a swallowable, non-surgical weight management device that operates through a different mechanism than traditional bariatric surgery. The product consists of a capsule containing a deflated balloon that is swallowed by the patient, then inflated in the stomach to promote satiety and reduce caloric intake.
The company also offers the Allurion Connected Care suite, which combines hardware with digital health tools, data analytics, and coaching support to help patients achieve weight loss goals. The system is designed to provide a reversible, minimally invasive option for individuals seeking medically supervised weight management.
How it makes money
Allurion’s business model centers on direct sales and physician adoption of its Allurion Gastric Balloon system. Revenue is generated through the sale of balloon devices to medical providers, hospitals, and bariatric centers, as well as from related consumables and software licensing. The company also generates revenue from international distribution partnerships and licensing agreements in various geographic markets.
The company targets both the private and insurance-reimbursed patient populations, with reimbursement coverage expanding in certain jurisdictions. Revenue recognition occurs as devices are sold and services are delivered through the Connected Care platform.
Where it sits in its industry
The weight loss technology and medical device sector includes surgical alternatives such as gastric bypass, gastric banding, and duodenal switch procedures, as well as pharmaceutical obesity treatments. Allurion’s non-surgical, reversible balloon approach represents a middle-ground option positioned between purely pharmacological treatments and invasive surgical bariatric procedures.
Competitors in the gastric balloon space include other device manufacturers offering similar or alternative weight loss solutions. The broader obesity treatment market is large and growing, driven by increasing obesity prevalence and rising demand for less invasive intervention options. Allurion’s Connected Care differentiation emphasizes behavioral coaching, digital monitoring, and patient engagement alongside the device itself.
How to research it
Investors and researchers can access Allurion’s filings through the U.S. Securities and Exchange Commission EDGAR database using CIK 1964979. The company’s 10-K annual reports detail business operations, financial performance, market opportunity, competitive positioning, and regulatory status. 10-Q quarterly reports provide updates on recent financial results and business developments.
The company’s investor relations website and earnings call transcripts offer management commentary on strategy, market penetration, reimbursement progress, and clinical outcomes. Healthcare investors may also review published clinical data and real-world evidence supporting the Allurion Balloon’s safety and efficacy profile.